Who owns Air Salonpas?
Air Salonpas is owned by Hisamitsu Pharmaceutical (Japan, TSE: 4530).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Evidence: Hisamitsu Pharmaceutical Group Integrated Report 2025, Hisamitsu Pharmaceutical Co., Inc. Last checked .
Key facts
- Current owner
- Hisamitsu Pharmaceutical Co., Inc. reported
- Owner HQ
- 🇯🇵 Japan
- Origin
- 🇯🇵 Japan
- Founded
- 1963
- Category
- Consumer health › Over-the-counter medicine › Pain relief
- Parent ticker
- TSE: 4530
- Last verified
- · 1 sources
About Air Salonpas
Air Salonpas is a Hisamitsu product in the Salonpas family, listed in the company's integrated report among its major products as launched in 1963. The report also records Hisamitsu handing out samples of Air Salonpas at sponsored marathons and sports events in Japan, where the Salonpas name is used heavily in sponsorship and promotion.
Ownership timeline of Air Salonpas
- Current owner Hisamitsu Pharmaceutical [1] reported
Where Air Salonpas sits in Hisamitsu Pharmaceutical
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Hisamitsu Pharmaceutical ownership tree →
See the full Hisamitsu Pharmaceutical brand portfolio (3) →
Other brands owned by Hisamitsu Pharmaceutical
Hisamitsu Pharmaceutical controls 3 brands on Brandtree, 3 of them in consumer health.
Also in consumer health
Other brands in pain relief, and who owns them
The 34 brands in pain relief on Brandtree belong to 19 owners. The largest is Haleon, with 3; Hisamitsu Pharmaceutical has 3.
| Brand | Owner | Owner based in |
|---|---|---|
| Advil | Haleon | 🇬🇧 United Kingdom |
| Motrin | Kenvue | 🇺🇸 United States |
| Dafalgan | Taisho Pharmaceutical | 🇯🇵 Japan |
| Mentho Plus | Emami | 🇮🇳 India |
| Bufferin (United States) | Genomma Lab | 🇲🇽 Mexico |
| Doril | Hypera | 🇧🇷 Brazil |
| Daleron | Krka | 🇸🇮 Slovenia |
| Kunyit Asam Sido Muncul | Sido Muncul | 🇮🇩 Indonesia |
About the owner: Hisamitsu Pharmaceutical
Hisamitsu Pharmaceutical is a publicly listed company headquartered in Japan, founded in 1847. Brandtree records 3 brands under its control, and it is listed as TSE: 4530.
Hisamitsu Pharmaceutical is a Japanese drug maker, listed in Tokyo, built around transdermal patches. Its integrated report gives the founding year as 1847, with head offices in Kyushu (main) and Tokyo, and traces its patch business to Asahi Mankinko in 1907. It also sells prescription patches through Noven Pharmaceuticals in the United States. Only its over-the-counter pain-relief brands are recorded here.
Hisamitsu Pharmaceutical: full profile, brands and acquisition history →
🇯🇵 Air Salonpas and other Japanese brands
Brandtree records a controlling owner for 437 brands that began in Japan. 21 of them (5%) are now controlled by a company headquartered in another country; Air Salonpas is not one of them.
- Ammeltz — Kobayashi Pharmaceutical 🇯🇵
- Biofermin — Taisho Pharmaceutical 🇯🇵
- Daiichi Sankyo Stomach Medicine — Daiichi Sankyo Healthcare 🇯🇵
- Jelly Monster — Okamoto Industries 🇯🇵
- "K" Line — K Line 🇯🇵
- ABEMA — CyberAgent 🇯🇵
Frequently asked questions
Who is the parent company of Air Salonpas?
The parent company of Air Salonpas is Hisamitsu Pharmaceutical, a publicly listed company headquartered in Japan.
Is Air Salonpas Japanese?
Yes. Air Salonpas originated in Japan in 1963 and its owner, Hisamitsu Pharmaceutical, is also headquartered in Japan.
Is Air Salonpas still owned by Hisamitsu Pharmaceutical?
Yes. As of 3 October 2026, Air Salonpas is still owned by Hisamitsu Pharmaceutical. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Hisamitsu Pharmaceutical Group Integrated Report 2025 — Hisamitsu Pharmaceutical Co., Inc., Annual report; retrieved 3 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.